Rachel Haurwitz

Rachel Haurwitz, Co-founder and CEO of Caribou Biosciences, discusses using CRISPR to engineer human immune cells to fight cancer. Topics include the journey of CRISPR from breakthrough to FDA approval, enhancing CRISPR's effectiveness, balancing affinity in CRISPR editing, challenges in CAR T-cell therapies for cancer, and reflections on career shifts and gene complexities.

Rachel Haurwitz, the President & CEO of Caribou Biosciences, dives into the future of CRISPR and CAR T therapies. As a pioneer in genome editing, she discusses the transformative potential of off-the-shelf CAR T solutions, currently being tested in multiple clinical trials. Rachel reflects on her journey from co-founding the company at just 26, the importance of strategic partnerships, and navigating the biotech landscape. She also emphasizes the need for diversity and the evolving dynamics in biotech entrepreneurship.